- Home
- PEB vs ETNB Comparison
PEB vs ETNB Comparison
Compare PEB & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEB
- ETNB
- Stock Information
- Founded
- PEB 2009
- ETNB 2018
- Country
- PEB United States
- ETNB United States
- Employees
- PEB N/A
- ETNB N/A
- Industry
- PEB Real Estate Investment Trusts
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- PEB Real Estate
- ETNB Health Care
- Exchange
- PEB Nasdaq
- ETNB Nasdaq
- Market Cap
- PEB 1.1B
- ETNB 1.0B
- IPO Year
- PEB 2009
- ETNB 2019
- Fundamental
- Price
- PEB $9.62
- ETNB $10.25
- Analyst Decision
- PEB Hold
- ETNB Strong Buy
- Analyst Count
- PEB 6
- ETNB 8
- Target Price
- PEB $12.05
- ETNB $26.43
- AVG Volume (30 Days)
- PEB 2.1M
- ETNB 2.2M
- Earning Date
- PEB 07-23-2025
- ETNB 08-04-2025
- Dividend Yield
- PEB 0.42%
- ETNB N/A
- EPS Growth
- PEB N/A
- ETNB N/A
- EPS
- PEB N/A
- ETNB N/A
- Revenue
- PEB $1,459,506,000.00
- ETNB N/A
- Revenue This Year
- PEB $1.63
- ETNB N/A
- Revenue Next Year
- PEB $3.39
- ETNB N/A
- P/E Ratio
- PEB N/A
- ETNB N/A
- Revenue Growth
- PEB 2.19
- ETNB N/A
- 52 Week Low
- PEB $7.42
- ETNB $4.16
- 52 Week High
- PEB $15.12
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- PEB 54.27
- ETNB 67.79
- Support Level
- PEB $8.80
- ETNB $9.81
- Resistance Level
- PEB $9.22
- ETNB $10.50
- Average True Range (ATR)
- PEB 0.29
- ETNB 0.70
- MACD
- PEB -0.00
- ETNB 0.07
- Stochastic Oscillator
- PEB 67.03
- ETNB 91.65
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).